Abstract
It is estimated that 50% of patients who have undergone ileal pouch – anal anastomosis (IPAA) surgery for UC will develop at least one episode of pouchitis. The risk of developing pouchitis is much higher in patients with preoperative extraintestinal manifestations and primary sclerosing cholangitis. In acute pouchtis metronidazole or ciprofloxacin have shown efficacy, however there is some evidence that ciprofloxacin may have better and has less toxic. In patients with chronic pouchitis antibiotics are less effective, and maintenance therapy may be required. In cases of refractoriness to conventional therapy a combination of two antibiotics for a prolonged period or infliximab may be effective. Starting maintenance treatment with highly concentrated probiotics is recommended as primary and secondary prophylaxis.
Keywords: Pouchitis, Antibiotics, Treatment, Probiotics, Tumor Necrosis Factor, Sulfate reducing bacteria, ESBL, Azathioprine
Current Drug Targets
Title: How to Manage Pouchitis in Ulcerative Colitis?
Volume: 12 Issue: 10
Author(s): F. Magro, S. Lopes, S. Rodrigues and I. Azevedo
Affiliation:
Keywords: Pouchitis, Antibiotics, Treatment, Probiotics, Tumor Necrosis Factor, Sulfate reducing bacteria, ESBL, Azathioprine
Abstract: It is estimated that 50% of patients who have undergone ileal pouch – anal anastomosis (IPAA) surgery for UC will develop at least one episode of pouchitis. The risk of developing pouchitis is much higher in patients with preoperative extraintestinal manifestations and primary sclerosing cholangitis. In acute pouchtis metronidazole or ciprofloxacin have shown efficacy, however there is some evidence that ciprofloxacin may have better and has less toxic. In patients with chronic pouchitis antibiotics are less effective, and maintenance therapy may be required. In cases of refractoriness to conventional therapy a combination of two antibiotics for a prolonged period or infliximab may be effective. Starting maintenance treatment with highly concentrated probiotics is recommended as primary and secondary prophylaxis.
Export Options
About this article
Cite this article as:
Magro F., Lopes S., Rodrigues S. and Azevedo I., How to Manage Pouchitis in Ulcerative Colitis?, Current Drug Targets 2011; 12(10) . https://dx.doi.org/10.2174/138945011796818144
DOI https://dx.doi.org/10.2174/138945011796818144 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Osmoadaptation of Mammalian Cells - An Orchestrated Network of Protective Genes
Current Genomics New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Viral Encephalitis in Adults: A Narrative Review
Reviews on Recent Clinical Trials Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Non-Invasive Biomarkers of Lung Inflammation in Smoking Subjects
Current Medicinal Chemistry DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?
Current Pharmaceutical Design Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Acknowledgements to the Reviewers:
Inflammation & Allergy - Drug Targets (Discontinued) Novel RNAi Therapy - Intron-Derived MicroRNA Drugs
Drug Design Reviews - Online (Discontinued) Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptides Against Autoimmune Neurodegeneration
Current Medicinal Chemistry New Treatment Options Using 5-HT3 Receptor Antagonists in Rheumatic Diseases
Current Topics in Medicinal Chemistry The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia
Current Pharmaceutical Biotechnology Dendrimers Effects on the Immune System: Insights into Toxicity and Therapeutic Utility
Current Pharmaceutical Design Giant Cell Arteritis (GCA): Pathogenesis, Clinical Aspects and Treatment Approaches
Current Rheumatology Reviews Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design